Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and NeckBarbara Burtness, José Trigo, Tomoya Yokota et al.|JAMA Oncology|2019Cited by 43
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trialRobert I. Haddad, Thomas Gauler, J. Guigay et al.|Oral Oncology|2019Cited by 10